SubHero Banner

Tracleer® (bosentan) – New formulation approval

September 6, 2017 – Actelion announced the FDA approval of Tracleer (bosentan) tablet for oral suspension, to support a new indication for the treatment of pulmonary arterial hypertension (PAH) [WHO Group I] in pediatric patients ≥ 3 years old with idiopathic or congenital PAH to improve pulmonary vascular resistance, which is expected to result in an improvement in exercise ability.

Download PDF